08:40:04 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-12 Kvartalsrapport 2024-Q3
2024-08-21 Kvartalsrapport 2024-Q2
2024-05-20 Ordinarie utdelning SCIB 0.00 SEK
2024-05-17 Årsstämma 2024
2024-05-09 Kvartalsrapport 2024-Q1
2024-02-22 Bokslutskommuniké 2023
2023-11-10 Kvartalsrapport 2023-Q3
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-19 Ordinarie utdelning SCIB 0.00 SEK
2023-05-17 Årsstämma 2023
2023-05-10 Kvartalsrapport 2023-Q1
2023-02-13 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-19 Ordinarie utdelning SCIB 0.00 SEK
2022-05-18 Årsstämma 2022
2022-05-12 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-11 Kvartalsrapport 2021-Q3
2021-09-07 Extra Bolagsstämma 2021
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-19 Ordinarie utdelning SCIB 0.00 SEK
2021-05-18 Årsstämma 2021
2021-05-12 Kvartalsrapport 2021-Q1
2021-02-19 Bokslutskommuniké 2020
2020-11-12 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-06-17 Årsstämma 2020
2020-05-15 Ordinarie utdelning SCIB 0.00 SEK
2020-05-05 Kvartalsrapport 2020-Q1
2020-04-29 Extra Bolagsstämma 2020
2020-02-21 Bokslutskommuniké 2019
2019-11-13 Kvartalsrapport 2019-Q3
2019-08-22 Kvartalsrapport 2019-Q2
2019-05-17 Ordinarie utdelning SCIB 0.00 SEK
2019-05-16 Årsstämma 2019
2019-05-10 Kvartalsrapport 2019-Q1
2019-02-20 Bokslutskommuniké 2018
2018-11-13 Kvartalsrapport 2018-Q3
2018-08-20 Kvartalsrapport 2018-Q2
2018-05-17 Ordinarie utdelning SCIB 0.00 SEK
2018-05-16 Årsstämma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-02-20 Bokslutskommuniké 2017
2017-11-15 Extra Bolagsstämma 2017
2017-11-10 Kvartalsrapport 2017-Q3
2017-08-18 Kvartalsrapport 2017-Q2
2017-05-17 Ordinarie utdelning SCIB 0.00 SEK
2017-05-16 Årsstämma 2017
2017-05-10 Kvartalsrapport 2017-Q1
2017-02-17 Bokslutskommuniké 2016
2016-11-14 Kvartalsrapport 2016-Q3
2016-08-19 Kvartalsrapport 2016-Q2
2016-05-17 Ordinarie utdelning SCIB 0.00 SEK
2016-05-16 Årsstämma 2016
2016-05-13 Kvartalsrapport 2016-Q1
2016-02-19 Bokslutskommuniké 2015
2015-11-12 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-05-06 Kvartalsrapport 2015-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
SciBase Holding är verksamt inom medicinteknik. Koncernen är specialiserad inom hantering av cancerdiagnostik, främst inriktat mot behandling och upptäckandet av diverse melanom. Bolaget har utvecklat en elektrisk handhållen sond som analyserar mätsignalen för att upptäcka specifika förändringar i kroppens hudvävnad. Huvudkontoret ligger i Stockholm.
2021-12-22 08:00:00

STOCKHOLM, SWEDEN, - December 22, 2021 - SciBase Holding AB ("SciBase") [STO:SCIB], a leading developer of augmented intelligence-based solutions for skin disorders,  announced today that a request for an appropriate Medicare payment assignment for the Nevisense procedure has been submitted to "National Government Services" (NGS), the Medicare Administrative Contractor with carrier jurisdiction responsibility for New York and several other states.

In July 2021, the American Medical Association (AMA) assigned a Category III CPT[® ]code for the Nevisense melanoma detection test that has been used by providers to report the use since then.

The request was submitted to NGS based on provider usage in the New York region.  NGS holds the Medicare contract for New York, Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, Illinois, Minnesota and Wisconsin. A decision regarding rate assignment within NGS may be implemented in one or more of NGS jurisdictions. 

"Coverage and payment from CMS are important for new procedures and technology such as ours, so this submission is an important milestone for SciBase and for Nevisense in the U.S.," said Simon Grant, CEO of SciBase. "Establishing a payment rate with NGS represents a significant opportunity for SciBase as they cover several regions with significant potential, which would allow providers to utilize this medically necessary technology in these regions. We believe that Nevisense can play a central role in improving skin cancer detection in the U.S., and especially for the important patient demographic covered by Medicare."

For more information please contact:
Simon Grant, CEO SciBase
Tel: +46 72 887 43 99
Email: simon.grant@scibase.com 

Certified Advisor:
Vator Securities

Tel: +46 8 580 065 99

Email: ca@vatorsec.se

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on December 22, 2021.

About SciBase and Nevisense
SciBase is a global medical technology company headquartered in Stockholm, Sweden, that has developed a unique point of care platform for the non-invasive detection of skin cancer and other skin conditions. SciBase is a pioneer within augmented intelligence, combining artificial intelligence with Electrical Impedance Spectroscopy (EIS) to provide objective information that assists dermatologists and others in clinical decision-making. SciBase's products include Nevisense and Nevisense Go and to date the platform addresses the areas of melanoma detection, non-melanoma skin cancer detection and skin barrier assessment. Nevisense is the only FDA-approved device for the detection of melanoma and the only MDR-approved technology for skin cancer detection in Europe. SciBase's technology is based on more than 20 years of academic research at the Karolinska Institute in Stockholm, Sweden. For more information please visit www.scibase.com.